clinical trials glp-1 Receptor Agonist Market to Grow at 17.5% CAGR till 2035 The GLP-1 Clinical Trial Landscape

Hence, we hypothesised that GLP-1 signalling in the OB could control the neural circuitry that regulates energy homeostasis in the context of metabolic disorders

Cardiovascular safety has not been definitively established because the LIGHT cardiovascular outcomes trial was terminated early

Sleep apnoea, a condition in which breathing repeatedly stops and starts during sleep, is significantly more common in men than in women, and is associated with fatigue, poor cognitive function, elevated cardiovascular risk, and reduced testosterone

Thus the results of this test will help to create awareness about G6PD deficiency in the society